Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer. 2010

Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
Department of Pharmacy, China Medical University, Taichung, Taiwan.

BACKGROUND Bone metastases are the most critical complication of prostate cancer (PCa), resulting in severe morbidity and mortality. Tumor necrosis factor receptor superfamily member 11b (TNFRSF11B) is a critical regulator between PCa cells and the bone environment. Recently, TNFRSF11B rs10505346 has been implicated in PCa risk in the Cancer Genetic Markers of Susceptibility genomewide association study. However, the association between this variant and biochemical failure in PCa patients receiving radical prostatectomy (RP) has not been determined. METHODS Associations of TNFRSF11B rs10505346 with age at diagnosis, preoperative prostate-specific antigen (PSA) level, Gleason score, pathologic stage, surgical margin, and PSA recurrence were evaluated in a cohort of 314 localized PCa patients receiving RP. The prognostic significance on PSA recurrence was assessed by Kaplan-Meier analysis and Cox regression model. RESULTS The mean level of preoperative PSA and the relative risks of PSA recurrence after RP were lower in individuals with T allele than in those with the G allele at TNFRSF11B rs10505346 (P = 0.019 and 0.014, respectively). The T allele of rs10505346 remained a protective factor against PSA recurrence (P = 0.022) in multivariate Cox regression model after considering all clinicopathological risk factors except PSA level. CONCLUSIONS Our data suggest that TNFRSF11B rs10505346 is associated with PSA level and might be a prognostic factor for the recurrence of PSA in PCa patients receiving RP.

UI MeSH Term Description Entries
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
June 2012, International journal of immunogenetics,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
January 2013, Journal of genetic syndromes & gene therapy,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
January 1995, Journal of inflammation,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
January 2009, Advances in experimental medicine and biology,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
May 2009, Immunological reviews,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
November 1999, Genomics,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
January 2002, Immunologic research,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
October 2020, World journal of hepatology,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
May 1999, The Journal of biological chemistry,
Bo-Ying Bao, and Victor C Lin, and Shu-Hung Huang, and Jiunn-Bey Pao, and Ta-Yuan Chang, and Te-Ling Lu, and Yu-Hsuan Lan, and Lu-Min Chen, and Wen-Chien Ting, and Wen-Hui Yang, and Chi-Jeng Hsieh, and Shu-Pin Huang
January 2013, ISRN oncology,
Copied contents to your clipboard!